BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Galapagos announced that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim.
David Smith, CEO Galapagos Services, commented, “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading research-based pharmaceutical companies and a new integrated drug discovery client to BioFocus. It is testament to the strength and depth of BioFocus’ drug discovery capabilities and expertise in this particular gene family.”
